July's top stories: Merck CMV Phase III trial, Sanofi vaccine study results

Merck enrolled the first patient in its global Phase III clinical trial of letermovir for the prevention of cytomegalovirus infection in high-risk bone marrow transplant patients, while Sanofi Pasteur reported positive results from its Phase III deng…
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news